FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018888303> ?p ?o ?g. }

• W2018888303 abstract "To estimate the number of non-Hispanic white individuals in the United States avoiding legal blindness and visual impairment from neovascular age-related macular degeneration (AMD) with ranibizumab availability.Modeling of visual acuity outcomes from phase 3 ranibizumab trials to incidence rates of neovascular AMD from population-based studies.If no treatment were given, of the 103 582 individuals developing neovascular AMD for which ranibizumab would be indicated and available, 16 268 would become legally blind in 2 years. Monthly ranibizumab would reduce the incidence of legal blindness in 2 years by 72% (95% confidence interval [CI], 70% to 74%) to 4484 individuals. If no treatment were given, 34 702 would become visually impaired. Monthly ranibizumab would reduce the incidence of visual impairment in 2 years by 37% (95% CI, 35% to 39%) to 21 919 cases.Ranibizumab should have a substantial effect on reducing the magnitude of legal blindness and visual impairment within 2 years after diagnosis of neovascular AMD among non-Hispanic white individuals in the United States. Although racial subgroups other than non-Hispanic whites were not considered (because there is limited information in the literature regarding incidence rates of choroidal neovascularization in other populations) and although these results assume access to and application of monthly ranibizumab for 2 years, the number of individuals developing legal blindness or vision impairment from neovascular AMD should be reduced dramatically if monthly ranibizumab is applied when indicated." @default.
• W2018888303 created "2016-06-24" @default.
• W2018888303 creator A5017512310 @default.
• W2018888303 creator A5018773741 @default.
• W2018888303 creator A5024474312 @default.
• W2018888303 creator A5039879095 @default.
• W2018888303 creator A5040075744 @default.
• W2018888303 creator A5046921541 @default.
• W2018888303 creator A5050148700 @default.
• W2018888303 creator A5067278845 @default.
• W2018888303 creator A5070015133 @default.
• W2018888303 creator A5083440287 @default.
• W2018888303 date "2011-06-13" @default.
• W2018888303 modified "2023-10-17" @default.
• W2018888303 title "Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization" @default.
• W2018888303 cites W109974915 @default.
• W2018888303 cites W1521704129 @default.
• W2018888303 cites W1601975653 @default.
• W2018888303 cites W1802218256 @default.
• W2018888303 cites W1987183752 @default.
• W2018888303 cites W200886222 @default.
• W2018888303 cites W2037780881 @default.
• W2018888303 cites W2068742492 @default.
• W2018888303 cites W2068943402 @default.
• W2018888303 cites W2073559780 @default.
• W2018888303 cites W2075984382 @default.
• W2018888303 cites W2080886828 @default.
• W2018888303 cites W2108749205 @default.
• W2018888303 cites W2122664355 @default.
• W2018888303 cites W2124415048 @default.
• W2018888303 cites W2140481308 @default.
• W2018888303 cites W2144523453 @default.
• W2018888303 cites W2164654252 @default.
• W2018888303 cites W2262759767 @default.
• W2018888303 cites W2275898654 @default.
• W2018888303 cites W2298592572 @default.
• W2018888303 cites W2598520882 @default.
• W2018888303 cites W2915852396 @default.
• W2018888303 doi "https://doi.org/10.1001/archophthalmol.2011.140" @default.
• W2018888303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21670337" @default.
• W2018888303 hasPublicationYear "2011" @default.
• W2018888303 type Work @default.
• W2018888303 sameAs 2018888303 @default.
• W2018888303 citedByCount "104" @default.
• W2018888303 countsByYear W20188883032012 @default.
• W2018888303 countsByYear W20188883032013 @default.
• W2018888303 countsByYear W20188883032014 @default.
• W2018888303 countsByYear W20188883032015 @default.
• W2018888303 countsByYear W20188883032016 @default.
• W2018888303 countsByYear W20188883032017 @default.
• W2018888303 countsByYear W20188883032018 @default.
• W2018888303 countsByYear W20188883032019 @default.
• W2018888303 countsByYear W20188883032020 @default.
• W2018888303 countsByYear W20188883032021 @default.
• W2018888303 countsByYear W20188883032022 @default.
• W2018888303 countsByYear W20188883032023 @default.
• W2018888303 crossrefType "journal-article" @default.
• W2018888303 hasAuthorship W2018888303A5017512310 @default.
• W2018888303 hasAuthorship W2018888303A5018773741 @default.
• W2018888303 hasAuthorship W2018888303A5024474312 @default.
• W2018888303 hasAuthorship W2018888303A5039879095 @default.
• W2018888303 hasAuthorship W2018888303A5040075744 @default.
• W2018888303 hasAuthorship W2018888303A5046921541 @default.
• W2018888303 hasAuthorship W2018888303A5050148700 @default.
• W2018888303 hasAuthorship W2018888303A5067278845 @default.
• W2018888303 hasAuthorship W2018888303A5070015133 @default.
• W2018888303 hasAuthorship W2018888303A5083440287 @default.
• W2018888303 hasBestOaLocation W20188883031 @default.
• W2018888303 hasConcept C118487528 @default.
• W2018888303 hasConcept C118552586 @default.
• W2018888303 hasConcept C119767625 @default.
• W2018888303 hasConcept C120665830 @default.
• W2018888303 hasConcept C121332964 @default.
• W2018888303 hasConcept C141071460 @default.
• W2018888303 hasConcept C2776403814 @default.
• W2018888303 hasConcept C2776694085 @default.
• W2018888303 hasConcept C2777802072 @default.
• W2018888303 hasConcept C2778257484 @default.
• W2018888303 hasConcept C2780929884 @default.
• W2018888303 hasConcept C2781100027 @default.
• W2018888303 hasConcept C2781359195 @default.
• W2018888303 hasConcept C2781372952 @default.
• W2018888303 hasConcept C2908647359 @default.
• W2018888303 hasConcept C61511704 @default.
• W2018888303 hasConcept C71924100 @default.
• W2018888303 hasConcept C99454951 @default.
• W2018888303 hasConceptScore W2018888303C118487528 @default.
• W2018888303 hasConceptScore W2018888303C118552586 @default.
• W2018888303 hasConceptScore W2018888303C119767625 @default.
• W2018888303 hasConceptScore W2018888303C120665830 @default.
• W2018888303 hasConceptScore W2018888303C121332964 @default.
• W2018888303 hasConceptScore W2018888303C141071460 @default.
• W2018888303 hasConceptScore W2018888303C2776403814 @default.
• W2018888303 hasConceptScore W2018888303C2776694085 @default.
• W2018888303 hasConceptScore W2018888303C2777802072 @default.
• W2018888303 hasConceptScore W2018888303C2778257484 @default.
• W2018888303 hasConceptScore W2018888303C2780929884 @default.
• W2018888303 hasConceptScore W2018888303C2781100027 @default.
• W2018888303 hasConceptScore W2018888303C2781359195 @default.
• W2018888303 hasConceptScore W2018888303C2781372952 @default.

• next